Paper48661
Letter: In-vitro resotration by levamisole of thymus-derived lymphocyte function in Hodgkin's disease.
Biniaminov M and 1 other. Lancet, 1975. Cited by 57 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Letter: In-vitro resotration by levamisole of thymus-derived lymphocyte function in Hodgkin's disease. Papers, record 48661. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/48661
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Letter: In-vitro resotration by levamisole of thymus-derived lymphocyte function in Hodgkin's disease.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hodgkin Disease | Major topic |
| Levamisole | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Humans | |
| Immune Adherence Reaction | |
| In Vitro Techniques | |
| Leukocyte Count | |
| Sheep |
Source PubMed
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 1,098,727 | Immunopotentiation with levamisole in resectable bronchogenic carcinoma: a double-blind controlled trial; Study Group for Bronchogenic Carcinoma. | Br Med J | 1975 | https://conductscience.org/library/papers/1098727 | PubMed |
| 908,176 | The effects of azathioprine and levamisole on rosette-forming cells of healthy subjects and cancer patients. | Clin Exp Immunol | 1977 | https://conductscience.org/library/papers/908176 | PubMed |
| 891,036 | Ferritin on the surface of lymphocytes in Hodgkin's disease patients. A possible blocking substance removed by levamisole. | Clin Exp Immunol | 1977 | https://conductscience.org/library/papers/891036 | PubMed |
| 791,550 | In vitro reversal of cellular unresponsiveness induced by levamisole. | Clin Exp Immunol | 1976 | https://conductscience.org/library/papers/791550 | PubMed |
| 321,165 | Restoration by levamisole of low E-rosette forming cells in patients suffering from various diseases. | Clin Exp Immunol | 1977 | https://conductscience.org/library/papers/321165 | PubMed |
| 312,252 | Inhibition of the E-rosette formation of T-lymphocytes by aggregated human IgG and restoration by levamisole. | Immunology | 1978 | https://conductscience.org/library/papers/312252 | PubMed |
| 306,223 | Defective neutrophil chemotaxis and raised serum ige levels in a child with recurrent bacterial infections and eczema. Influence of levamisole. | Arch Dis Child | 1978 | https://conductscience.org/library/papers/306223 | PubMed |
| 272,084 | Levamisole as an immunotherapeutic agent in the treatment of cancer. | World J Surg | 1977 | https://conductscience.org/library/papers/272084 | PubMed |
| 75,542 | Whipple's disease in a female with impaired cell-mediated immunity unresponsive to co-trimoxazole and levamisole therapy. | Postgrad Med J | 1978 | https://conductscience.org/library/papers/75542 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/48661
GET https://conductscience.org/api/papers/v1/48661/authors